Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.7 Million EUR | -1.08% |
| 2022 | 13.85 Million EUR | -2.72% |
| 2021 | 14.24 Million EUR | 2.29% |
| 2020 | 13.92 Million EUR | 104.63% |
| 2019 | 6.8 Million EUR | 51.35% |
| 2018 | 4.49 Million EUR | 76.15% |
| 2017 | 2.55 Million EUR | 103.43% |
| 2016 | 1.25 Million EUR | 16.31% |
| 2015 | 1.07 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 13.26 Million EUR | 0.0% |
| 2023 Q4 | 13.7 Million EUR | 0.0% |
| 2023 FY | 13.7 Million EUR | -1.08% |
| 2022 FY | 13.85 Million EUR | -2.72% |
| 2022 Q2 | 13.5 Million EUR | 0.0% |
| 2022 Q4 | 13.85 Million EUR | 0.0% |
| 2021 FY | 14.24 Million EUR | 2.29% |
| 2021 Q4 | 14.24 Million EUR | 0.0% |
| 2021 Q2 | 13.89 Million EUR | 0.0% |
| 2020 Q4 | 13.92 Million EUR | 0.0% |
| 2020 Q2 | 10.96 Million EUR | 0.0% |
| 2020 FY | 13.92 Million EUR | 104.63% |
| 2019 Q2 | 6.65 Million EUR | 0.0% |
| 2019 Q4 | 6.8 Million EUR | 0.0% |
| 2019 FY | 6.8 Million EUR | 51.35% |
| 2018 FY | 4.49 Million EUR | 76.15% |
| 2018 Q4 | 4.49 Million EUR | 0.0% |
| 2018 Q2 | 2.77 Million EUR | 0.0% |
| 2017 Q2 | 1.92 Million EUR | 0.0% |
| 2017 Q4 | 2.55 Million EUR | 0.0% |
| 2017 FY | 2.55 Million EUR | 103.43% |
| 2016 Q4 | 1.25 Million EUR | 0.0% |
| 2016 FY | 1.25 Million EUR | 16.31% |
| 2015 FY | 1.07 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -98.322% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 89.54% |
| Adocia SA | 31.87 Million EUR | 56.988% |
| Aelis Farma SA | 13.08 Million EUR | -4.801% |
| Biophytis S.A. | 15.84 Million EUR | 13.509% |
| Advicenne S.A. | 24.37 Million EUR | 43.767% |
| genOway Société anonyme | 14.45 Million EUR | 5.197% |
| IntegraGen SA | 5.97 Million EUR | -129.239% |
| Medesis Pharma S.A. | 6.42 Million EUR | -113.315% |
| Neovacs S.A. | 3.71 Million EUR | -269.276% |
| NFL Biosciences SA | 3.62 Million EUR | -278.603% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -102.113% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -314.126% |
| Sensorion SA | 13.22 Million EUR | -3.634% |
| Theranexus Société Anonyme | 5.01 Million EUR | -173.275% |
| TME Pharma N.V. | 2.78 Million EUR | -392.208% |
| TheraVet SA | 1.48 Million EUR | -823.102% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 33.027% |
| argenx SE | 402.79 Million EUR | 96.597% |
| BioSenic S.A. | 32.26 Million EUR | 57.513% |
| Celyad Oncology SA | 9.97 Million EUR | -37.382% |
| DBV Technologies S.A. | 38.74 Million USD | 64.62% |
| Galapagos NV | 1.56 Billion EUR | 99.122% |
| Genfit S.A. | 105.92 Million EUR | 87.058% |
| GeNeuro SA | 20.13 Million EUR | 31.936% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -59.173% |
| Innate Pharma S.A. | 132.29 Million EUR | 89.638% |
| Inventiva S.A. | 101.59 Million EUR | 86.507% |
| MaaT Pharma SA | 22.46 Million EUR | 38.981% |
| MedinCell S.A. | 77.77 Million EUR | 82.374% |
| Nanobiotix S.A. | 95.74 Million EUR | 85.682% |
| Onward Medical N.V. | 25.69 Million EUR | 46.657% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 45.442% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 76.797% |
| Oxurion NV | 19.73 Million EUR | 30.543% |
| Pharming Group N.V. | 228.28 Million EUR | 93.995% |
| Poxel S.A. | 53.9 Million EUR | 74.568% |
| GenSight Biologics S.A. | 34.72 Million EUR | 60.526% |
| Transgene SA | 26.51 Million EUR | 48.305% |
| Financière de Tubize SA | 123.65 Million EUR | 88.914% |
| UCB SA | 6.56 Billion EUR | 99.791% |
| Valneva SE | 341.14 Million EUR | 95.982% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -201.473% |